Warning! GuruFocus detected
4 Severe warning signs
with RNA.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Avidity Biosciences Inc
NAICS : 541714
SIC : 2834
ISIN : US05370A1088
Share Class Description:
RNA: Ordinary SharesDescription
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 220.78 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 15.64 | |||||
| Beneish M-Score | -0.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -24.2 | |||||
| 3-Year EBITDA Growth Rate | -6 | |||||
| 3-Year EPS without NRI Growth Rate | -0.5 | |||||
| 3-Year FCF Growth Rate | -5.1 | |||||
| 3-Year Book Growth Rate | 14.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 196.43 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.53 | |||||
| 9-Day RSI | 48.65 | |||||
| 14-Day RSI | 48.84 | |||||
| 3-1 Month Momentum % | -2.2 | |||||
| 6-1 Month Momentum % | -30.04 | |||||
| 12-1 Month Momentum % | 29.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.73 | |||||
| Quick Ratio | 15.73 | |||||
| Cash Ratio | 15.32 | |||||
| Days Sales Outstanding | 44.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -35.9 | |||||
| Shareholder Yield % | -26.95 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -3477.44 | |||||
| Net Margin % | -2957.72 | |||||
| FCF Margin % | -2825.88 | |||||
| ROE % | -29.4 | |||||
| ROA % | -26.28 | |||||
| ROIC % | -651.47 | |||||
| 3-Year ROIIC % | -1442.39 | |||||
| ROC (Joel Greenblatt) % | -2297.2 | |||||
| ROCE % | -33.22 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 303.19 | |||||
| PB Ratio | 2.59 | |||||
| Price-to-Tangible-Book | 2.59 | |||||
| EV-to-EBIT | -5.84 | |||||
| EV-to-Forward-EBIT | -1.3 | |||||
| EV-to-EBITDA | -5.88 | |||||
| EV-to-Forward-EBITDA | -1.32 | |||||
| EV-to-Revenue | 202.94 | |||||
| EV-to-Forward-Revenue | 478.41 | |||||
| EV-to-FCF | -7.18 | |||||
| Price-to-GF-Value | 3.26 | |||||
| Price-to-Net-Current-Asset-Value | 2.63 | |||||
| Price-to-Net-Cash | 2.71 | |||||
| Earnings Yield (Greenblatt) % | -17.12 | |||||
| FCF Yield % | -8.31 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RNA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Avidity Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10.897 | ||
| EPS (TTM) ($) | -2.89 | ||
| Beta | 1.07 | ||
| 3-Year Sharpe Ratio | 0.56 | ||
| 3-Year Sortino Ratio | 1.18 | ||
| Volatility % | 76.98 | ||
| 14-Day RSI | 48.84 | ||
| 14-Day ATR ($) | 2.12909 | ||
| 20-Day SMA ($) | 30.51 | ||
| 12-1 Month Momentum % | 29.13 | ||
| 52-Week Range ($) | 21.56 - 56 | ||
| Shares Outstanding (Mil) | 120.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Avidity Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Avidity Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Avidity Biosciences Inc Frequently Asked Questions
What is Avidity Biosciences Inc(RNA)'s stock price today?
The current price of RNA is $30.84. The 52 week high of RNA is $56.00 and 52 week low is $21.56.
When is next earnings date of Avidity Biosciences Inc(RNA)?
The next earnings date of Avidity Biosciences Inc(RNA) is 2025-05-09 Est..
Does Avidity Biosciences Inc(RNA) pay dividends? If so, how much?
Avidity Biosciences Inc(RNA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers